Mumbai: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNPIN, NSE: SUNPHARMA, BSE: 524715), one of the world’s leading pharmaceutical companies, has announced the launch of its global innovative drug Ilumya® (Tildrakizumab) in India for the treatment of moderate-to-severe plaque psoriasis.
Already available in 35 countries, Ilumya® has been widely endorsed by dermatologists worldwide as a safe and effective biologic therapy. The drug has consistently demonstrated significant and long-lasting skin clearance, beginning soon after initiation and sustained over years.
Clinical Study In India
Sun Pharma conducted a clinical study involving 115 Indian patients with moderate-to-severe plaque psoriasis. Results showed:
- 75% skin clearance (PASI 75): Achieved by 62.3% at Week 12, 83.3% at Week 16, and 93.9% at Week 28.
- 90% skin clearance (PASI 90): Achieved by 26.3% at Week 12, 50% at Week 16, and 78.1% at Week 28.
- Patients received three subcutaneous injections of Tildrakizumab over 16 weeks (Day 1, Week 4, Week 16) and were followed for 28 weeks.
- Significant improvements were also observed in Dermatology Life Quality Index (DLQI) scores.
- The drug was well tolerated, with no immunogenicity concerns observed.
Expert Endorsements
Kirti Ganorkar, Managing Director of Sun Pharma, stated: “Ilumya offers a safe and effective treatment option for patients who are struggling to manage their moderate-to-severe plaque psoriasis. We are pleased to introduce this novel therapy in India from our global portfolio of innovative medicines.”
Dr. B. S. Chandrashekar, Chief Dermatologist and Managing Director at Cutis Academy of Cutaneous Sciences, Bengaluru, added: “In the Phase-3 trial, Tildrakizumab demonstrated significant improvements across all measures, with approximately 93.5% reduction in PASI score and pronounced skin clearance. These results showcase its benefits in improving the quality of life for psoriasis patients.”
Long-Term Efficacy
Ilumya® is the first IL-23 inhibitor to complete five years of study based on pooled analysis of two Phase 3 efficacy and safety extension trials. Data confirms that Ilumya® is a sustainable therapy option for patients requiring long-term treatment without loss of efficacy.
